Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population.
Reducing GWAS Complexity.
Risk Analysis of Prostate Cancer in PRACTICAL Consortium-Response.
A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer.
LocusExplorer: a user-friendly tool for integrated visualization of human genetic association data and biological annotations.
Analysis techniques in the presence of non-proportional hazards (PH); application to an ovarian cancer RCT with long-term follow-up.
The contribution of rare variation to prostate cancer heritability.
Identification of four new susceptibility loci for testicular germ cell tumour.
Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions.
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.
The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium.
High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer.
Genome-wide association study of prostate cancer-specific survival.
Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC.
Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers.
Prediction of individual genetic risk to prostate cancer using a polygenic score.
Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions.
Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.
Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.
Spatial genomic heterogeneity within localized, multifocal prostate cancer.
Family history and outcome of young patients with breast cancer in the UK (POSH study).
Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.
Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder.
The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer.
Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.
The evolutionary history of lethal metastatic prostate cancer.
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin.
An evaluation of the prognostic model PREDICT using the POSH cohort of women aged ⩽40 years at breast cancer diagnosis.
The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers.
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.
A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer.
Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
Identification of six new susceptibility loci for invasive epithelial ovarian cancer.
Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.
HES5 silencing is an early and recurrent change in prostate tumourigenesis.
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
Corrigendum to "Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study" [Eur Urol 2014;66:489-99].
Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort.
"It's all very well reading the letters in the genome, but it's a long way to being able to write": Men's interpretations of undergoing genetic profiling to determine future risk of prostate cancer.
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.
Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer.
Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.
Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis.
Obesity and the outcome of young breast cancer patients in the UK: the POSH study.
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25.
Prevention and early detection of prostate cancer.
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer.
A genome-wide pleiotropy scan for prostate cancer risk.
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.
Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer.
Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.
Generalizability of established prostate cancer risk variants in men of African ancestry.
Radiogenomics: radiobiology enters the era of big data and team science.
Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium.
Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.
Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies.
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers.
MRI breast screening in high-risk women: cancer detection and survival analysis.
Proffered papers and posters submitted to the Fifth International Symposium on Hereditary Breast and Ovarian Cancer, BRCA: Twenty Years of Advances.
Li-Fraumeni syndrome: cancer risk assessment and clinical management.
Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status.
Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease.
Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer.
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium.
Comprehensive functional annotation of 77 prostate cancer risk loci.
Telomere length shows no association with BRCA1 and BRCA2 mutation status.
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
Germline genetic variants associated with prostate cancer and potential relevance to clinical practice.
Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk.
Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond.
The genetic epidemiology of prostate cancer and its clinical implications.
Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease.
Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study.
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression.
A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk.
Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up.
Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study.
An assessment of the shared allelic architecture between type II diabetes and prostate cancer.
Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14.
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression.
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent.
Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk.
Stratified cancer screening: the practicalities of implementation.
Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort.
Reproductive decision-making in young female carriers of a BRCA mutation.
IMPACT Study: Targeted Prostate Cancer Screening.
Prostate cancer screening in BRCA and Lynch syndrome mutation carriers.
Stereotactic body radiotherapy for oligometastases.
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men.
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer.
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.
Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis.
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK).
Evaluating genetic risk for prostate cancer among Japanese and Latinos.
Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2.
Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families.
Beyond prostate-specific antigen - future biomarkers for the early detection and management of prostate cancer.
The role of genetic markers in the management of prostate cancer.
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study.
Germline BRCA1 mutations increase prostate cancer risk.
The role of BRCA1 and BRCA2 in prostate cancer.
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers.
Selected abstracts submitted to the Fourth International Symposium on Hereditary Breast and Ovarian Cancer.
Genetic variants associated with predisposition to prostate cancer and potential clinical implications.
Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations.
Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk.
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London.
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG).
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests.
Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data.
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.
Gene-gene interactions in breast cancer susceptibility.
ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.
Germline mutations in RAD51D confer susceptibility to ovarian cancer.
Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis.
Reply: ‘Hand pattern indicates risk of prostate cancer'.
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact.
Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG.
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.
Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness.
Genome-wide association study identifies new prostate cancer susceptibility loci.
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.
National Cancer Institute Prostate Cancer Genetics Workshop.
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening.
Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript.
Exploring the link between MORF4L1 and risk of breast cancer.
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.
Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.
Psychological impact and acceptability of magnetic resonance imaging and X-ray mammography: the MARIBS Study.
Ownership of uncertainty: healthcare professionals counseling and treating women from hereditary breast and ovarian cancer families who receive an inconclusive BRCA1/2 genetic test result.
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.
Hand pattern indicates prostate cancer risk.
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers.
Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer.
Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer.
Multicentric breast cancer: clonality and prognostic studies.
Validation of genome-wide prostate cancer associations in men of African descent.
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine.
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
Mutation and association analysis of GEN1 in breast cancer susceptibility.
Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies.
The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice.
Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses.
Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study.
Screening for prostate cancer: the way ahead.
The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.
Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation.
Dietary fat and early-onset prostate cancer risk.
Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives.
Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies.
Mutation analysis of the MSMB gene in familial prostate cancer.
Overexpression of RAD51 occurs in aggressive prostatic cancer.
Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).
Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study.
Multiple loci on 8q24 associated with prostate cancer susceptibility.
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.
Germ-line mutations in mismatch repair genes associated with prostate cancer.
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis.
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.
Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.
Dramatic response to platinum in a patient with cancer with a germline BRCA2 mutation.
Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study.
Unusual presentation of Lynch Syndrome.
Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer.
Childhood predictive genetic testing for Li-Fraumeni syndrome.
Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.
The G67E mutation in hMLH1 is associated with an unusual presentation of Lynch syndrome.
A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.
No evidence that GATA3 rs570613 SNP modifies breast cancer risk.
Identification of new genetic risk factors for prostate cancer.
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.
TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.
Sexual activity and prostate cancer risk in men diagnosed at a younger age.
Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer?
Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer.
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Genome-wide association studies in cancer.
Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance.
A pilot study of compositional analysis of the breast and estimation of breast mammographic density using three-dimensional T1-weighted magnetic resonance imaging.
SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design?
Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines.
Communicating genetics research results to families: problems arising when the patient participant is deceased.
Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium.
Multiple loci with different cancer specificities within the 8q24 gene desert.
No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.
Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers.
Diagnostic radiation procedures and risk of prostate cancer.
Accurate prediction of BRCA1 and BRCA2 heterozygous genotypes using expression profiling of lymphocytes after irradiation-induced DNA damage.
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Surveillance and treatment of malignancy in Bloom syndrome.
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
The accuracy of cancer diagnoses as reported in families with head and neck cancer: a case-control study.
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Multiple newly identified loci associated with prostate cancer susceptibility.
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays.
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Outcome of early detection and radiotherapy for occult spinal cord compression.
Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC).
Complex patterns of ETS gene alteration arise during cancer development in the human prostate.
Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.
A population-based audit of ethnicity and breast cancer risk in one general practice catchment area in North London, UK: implications for practice.
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.
Delivery of cancer genetics services: The Royal Marsden telephone clinic model.
Disclosure of genetics research results after the death of the patient participant: a qualitative study of the impact on relatives.
p53 therapy in a patient with Li-Fraumeni syndrome.
Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics.
A review of targeted screening for prostate cancer: introducing the IMPACT study.
Short report. The AIDIT and IMPACT conference 2006: Outcomes and future directions.
Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up.
Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls.
Delivering cancer genetics services--new ways of working.
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.
A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers.
Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their family.
Proteomic analysis of nipple aspirate fluid throughout the menstrual cycle in healthy pre-menopausal women.
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate.
AIDIT and IMPACT: building research collaborations in targeted prostate cancer screening.
Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation.
Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics.
Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls.
Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage.
Clinical outcome and service implications of screening women at increased breast cancer risk from a family history.
IMPACT and AIDIT: Strengthening Research Ties in Eastern Europe.
BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.
"Social separation" among women under 40 years of age diagnosed with breast cancer and carrying a BRCA1 or BRCA2 mutation.
Sweat-gland tumours: a clinical review of cases in one centre over 20 years.
Radiotherapy and genetic predisposition to breast cancer.
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Feasibility of familial PSA screening: psychosocial issues and screening adherence.
The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk.
Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Genotype phenotype correlation in Li-Fraumeni syndrome kindreds and its implications for management.
Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers.
Genetic predisposition to cancer: the consequences of a delayed diagnosis of Gorlin syndrome.
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Construction of tissue microarrays from prostate needle biopsy specimens.
Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics.
Men's decision-making about predictive BRCA1/2 testing: the role of family.
Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: patterns, priorities and problems.
The utility of digital rectal examination after radical radiotherapy for prostate cancer.
Early outcomes of active surveillance for localized prostate cancer.
Processing of radical prostatectomy specimens for correlation of data from histopathological, molecular biological, and radiological studies: a new whole organ technique.
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
Association between polymorphisms of the GPX1 gene and second primary tumours after index squamous cell cancer of the head and neck.
Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer.
Optimizing the diagnosis of prostate cancer in high-risk men: the supplementary biomarker approach.
Does genetic counseling have any impact on management of breast cancer risk?
Association between hormonal genetic polymorphisms and early-onset prostate cancer.
The proteomic approach to urological biomarkers.
Analysis of familial male breast cancer for germline mutations in CHEK2.
Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort.
Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer.
Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome.
Unravelling the genetics of prostate cancer.
ATM polymorphisms as risk factors for prostate cancer development.
BRCA1/2 predictive testing: a study of uptake in two centres.
The clinical genetics of prostate cancer.
Proteomics and urine analysis: a potential promising new tool in urology.
Healthy women from suspected hereditary breast and ovarian cancer families: the significant others in their lives.
We are talking, but are they listening? Communication patterns in families with a history of breast/ovarian cancer (HBOC).
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.
Developments in Clinical Practice: Follow up Clinic for BRCA Mutation Carriers: a Case Study Highlighting the "Virtual Clinic".
Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatment.
ATM protein overexpression in prostate tumors: possible role in telomere maintenance.
Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status.
Ductal approaches to assessment and management of women at high risk for developing breast cancer.
Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers.
An audit of screening for familial breast cancer before 50 years in the South Thames Region - have we got it right?
Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort.
Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinic.
Family stories and the use of heuristics: women from suspected hereditary breast and ovarian cancer (HBOC) families.
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Mutations in BRCA1 and BRCA2 and predisposition to prostate cancer.
Association between leptin receptor gene polymorphisms and early-onset prostate cancer.
Balancing autonomy and responsibility: the ethics of generating and disclosing genetic information.
Apoptosis, ageing and cancer susceptibility.
Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer.
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.
CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours.
Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome.
HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease.
Prostate-specific antigen in nipple aspiration fluid: menstrual cycle variability and correlation with serum prostate-specific antigen.
The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS).
Genetic testing for breast and ovarian cancer predisposition: cancer burden and responsibility.
The IARC TP53 database: new online mutation analysis and recommendations to users.
Influence of cytokine gene polymorphisms on the development of prostate cancer.
Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia.
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort.
Forum for Applied Cancer Education and Training (FACET).
A robust method for detecting CHK2/RAD53 mutations in genomic DNA.
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium.
Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer.
Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching.
No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours.
The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography?
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
Cellular characteristics of nipple aspiration fluid during the menstrual cycle in healthy premenopausal women.
Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer.
An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations-fluorescent mutation detection (F-MD).
A paradox: urgent BRCA genetic testing.
Apparent Mendelian inheritance of breast and colorectal cancer: chance, genetic heterogeneity or a new gene?
High risk genes predisposing to prostate cancer development-do they exist?
Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36. The CRC/BPG UK Familial Prostate Cancer Study Coordinators and Collaborators. The EU Biomed Collaborators.
Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Molecular markers for predicting prostate cancer stage and survival.
Genetic testing for cancer predisposition--an ongoing debate.
Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group.
The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
Screening hCHK2 for mutations.
Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers.
Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer.
Protocol for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer.
BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial.
No evidence of germline PTEN mutations in familial prostate cancer.
The value of rapid functional assays of germline p53 status in LFS and LFL families.
A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy?
Simultaneous breast cancer in non-identical Ashkenazi Jewish twins: management dilemmas when genetic testing is negative.
Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10.
BRCA1, BRCA2 and their possible function in DNA damage response.
Screening for hereditary cancer and genetic testing, epitomized by breast cancer.
BRCA1/2 carriers and endocrine risk modifiers.
Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival.
Cancer risks in BRCA2 mutation carriers.
BCL10 is rarely mutated in human prostate carcinoma, small-cell lung cancer, head and neck tumours, renal carcinoma and sarcomas. MPT Collaborators, St George's Hospital Collaborators.
Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer.
The role of genetic factors in predisposition to squamous cell cancer of the head and neck.
Genetic predisposition to prostate cancer.
Management of Breast Cancer in BRCA1/2 Mutation Carriers.
Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.
Germline PTEN mutations in Cowden syndrome-like families.
Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. CRC/BPG UK Familial Prostate Cancer Study Collaborators.
Family history of breast cancer: what do women understand and recall about their genetic risk?
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators.
Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation.
Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study.
No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.
Testing for the breast cancer predisposition gene, BRCA1.
Familial breast cancer: a controlled study of risk perception, psychological morbidity and health beliefs in women attending for genetic counselling.
Localization of the gene for Cowden disease to chromosome 10q22-23.
Prophylactic mastectomy for genetic predisposition to breast cancer: the proband's story.
Genetic testing in breast/ovarian cancer (BRCA1) families.
Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.
Progress in prostate cancer.
Developments in the study of familial breast cancer.
Germline mutations in the TP53 gene.
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome with pleiotropy?
Familial cancer syndromes.
The genetics of familial breast cancer and their practical implications.
Head and neck sarcomas: prognostic factors and implications for treatment.
Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings.
Ploidy and proliferative index in medulloblastoma: useful prognostic factors?
The role of TP53 in breast cancer development.
Predictive testing for germline mutations in the p53 gene: are all the questions answered?
Detection of point mutations in the p53 gene: comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroxylamine and osmium tetroxide techniques.
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome.
Intracardiac metastases from germ cell tumours--an unusual but important site of metastasis.
No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families.
The association of germ cell tumours of the testis with sarcoid-like processes.
Salvage radiotherapy in recurrent Hodgkin's disease.
The PCR revolution.
Hormone replacement therapy and survival after surgery for ovarian cancer.
Limb function following conservation treatment of adult soft tissue sarcoma.
Non-Hodgkin's lymphoma presenting with extradural spinal cord compression: functional outcome and survival.
Mimics of metastases from testicular tumours.
Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.
Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer.
Clonal analysis of morphological phenotype in cultured mammary epithelial cells from human milk.
Germline and somatic studies in the TP53 gene in breast and other cancers.